查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1454728

美容注射市场- 按类型（肉毒桿菌毒素、真皮填充剂（产品（透明质酸、羟基磷灰石钙）、应用（面部提升、除皱）））、性别、年龄组、最终用户和预测2024 - 2032

Aesthetic Injectables Market - By Type (Botulinum Toxin, Dermal Fillers (Product (Hyaluronic Acid, Calcium Hydroxyapatite), Application (Face Lift, Wrinkle Reduction))), Gender, Age Group, End-user & Forecast2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 240 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于注射技术的不断进步以及对现有治疗方法的认识不断增强，2024 年至 2032 年全球美容注射市场规模将以 10.2% 的CAGR增长。不断涌现的创新正在为解决从皱纹到脸部体积损失等各种美容问题提供更安全、更有效的解决方案。注射治疗的多功能性可满足广泛的美感需求，有助于吸引更广泛的消费者群体。随着消费者越来越了解其好处和可能性，市场将显着扩大。例如，2024 年 2 月，Merz Aesthetics 推出了 RADIESSE 的新用途，作为美容注射剂，旨在增强肩部区域的中度至重度皱纹。

美容注射剂产业根据类型、性别、年龄层、最终用户和地区进行分类。

就类型而言，由于对非侵入性美容手术的需求激增，真皮填充剂领域的市场价值在 2024 年至 2032 年间将实现 10.7% 的CAGR。对年轻外表的强烈渴望和人口老化的不断增长正在推动注射技术的进步。脸部除皱注射越来越受欢迎，因为它们提供了传统手术的便利替代方案，吸引了那些寻求无需停机就能恢復活力的人。随着全球越来越多的人选择这些手术，该细分市场将持续成长。

根据最终用户的情况，到2032 年，医院在美容注射剂行业将取得相当大的立足点。这是由于对在医院环境中进行的微创美容手术的需求不断增长所推动的，患者可以从先进的医疗设施和专家护理中受益。此外，医院对安全协议和无菌环境的高度重视与对病人安全和满意度的日益重视是一致的。随着越来越多的人寻求肉毒桿菌和皮肤填充剂等治疗方法，医院将成为主要提供者，进一步推动产品需求。

受多种因素的推动，包括中国和印度可支配收入的增加，以及美容手术在这两个国家变得越来越流行，亚太地区美容注射剂市场规模从 2024 年到 2032 年将呈现 12.2% 的CAGR。人们对美容和护肤意识的不断提高，加上技术的进步和人口老化的加剧，都刺激了对注射疗程的需求。整体而言，亚太地区动态的市场格局和人口趋势将有利于产业成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 老年人口不断增加
      • 已开发国家对脸部美学的认识与关注不断提高
      • 对微创美容手术的需求不断增加
      • 已开发国家的专业人员和设施数量不断增加
    • 产业陷阱与挑战
      • 与美容注射相关的高成本
      • 与这些程序相关的副作用
  • 成长潜力分析
  • 监管环境
  • 技术景观
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按类型，2018 - 2032

  • 主要趋势
  • 肉毒桿菌毒素
    • A型肉毒桿菌毒素
    • 肉毒桿菌B
  • 真皮填充剂
    • 依产品类型
      • 玻尿酸
      • 羟基磷灰石钙
      • 聚-L-乳酸
      • 聚甲基丙烯酸甲酯微球（PMMA）
      • 胶原
      • 脂肪填充剂
      • 其他真皮填充剂
    • 按申请
      • 脸部提升
      • 脸部矫正
      • 减少皱纹
      • 痤疮疤痕
      • 脂肪萎缩
      • 丰唇
      • 髋关节增强术
      • 丰胸
      • 手部年轻化
      • 阴茎增大
      • 眼睑整形术
      • 颈部和下巴提升术
      • 其他应用

第 6 章：市场估计与预测：按性别划分，2018 年 - 2032 年

  • 主要趋势
  • 女性
  • 男性

第 7 章：市场估计与预测：按年龄划分，2018 - 2032

  • 主要趋势
  • 15 - 30 次
  • 31 - 40
  • 41 - 50
  • 51 - 60
  • > 60

第 8 章：市场估计与预测：按最终用户划分，2018 年 - 2032 年

  • 主要趋势
  • 医院
  • 皮肤科诊所
  • 其他最终用户

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 中东和非洲其他地区

第 10 章：公司简介

  • AbbVie Inc (Allergan Plc.)
  • Bio-Med Private Limited
  • Bioxis Pharmaceuticals
  • Cytophil, Inc.
  • Galderma S.A.
  • Ipsen SA
  • Laboratories Vivacy SAS
  • Merz Pharma GmbH & Co. KGaA.
  • Mesoestetic
  • Sinclair Pharma (Huadong Medicine Co., Ltd)
  • Suneva Medical, Inc
  • Teoxane Laboratories
简介目录
Product Code: 8040

Global Aesthetic Injectables Market size will grow at 10.2% CAGR from 2024 to 2032, due to the ongoing advancements in injectable technologies coupled with the growing awareness of available treatments. Rising innovations are offering safer and more effective solutions for addressing various cosmetic concerns, from wrinkles to facial volume loss. The versatility of injectable treatments for catering to a wide range of aesthetic needs is helping attract a broader consumer base. With consumers becoming more informed about the benefits and possibilities, the market will expand significantly. For instance, in February 2024, Merz Aesthetics introduced a new use for RADIESSE as an aesthetic injectable designed to enhance moderate to severe wrinkles in the decollete region.

The aesthetic injectables industry is classified on the basis of type, gender, age group, end-user, and region.

In terms of type, the market value from the dermal fillers segment will secure a 10.7% CAGR between 2024 and 2032, attributed to the surge in the demand for non-invasive cosmetic procedures. The strong desire for youthful appearance and the growing aging population is driving advancements in injectable technologies. Face lift injectables have grown popular as they offer a convenient alternative to traditional surgery, appealing to those seeking rejuvenation without the downtime. With an increasing number of individuals opting for these procedures worldwide, the segment will witness sustained growth.

Based on the end-user, the hospital segment in the aesthetic injectables industry will achieve a considerable foothold by 2032. This is propelled by the growing demand for minimally invasive cosmetic procedures performed in hospital settings, where patients benefit from advanced medical facilities and expert care. Additionally, the strong emphasis of hospitals on safety protocols and sterile environments aligns with the increasing emphasis on patient safety and satisfaction. As more individuals seek treatments like Botox and dermal fillers, hospitals will become the primary providers, further driving the product demand.

Asia Pacific aesthetic injectables market size will exhibit a 12.2% CAGR from 2024 to 2032, fueled by several factors, including the increasing disposable incomes in China and India, where aesthetic procedures are becoming more popular. The rising awareness of beauty and skincare coupled with technological advancements and the growing aging population are fueling the demand for injectable treatments. Overall, the presence of dynamic market landscape and demographic trends in Asia Pacific will prove favorable for the industry growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Forecast parameters
  • 1.4 Data collection
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing elderly population
      • 3.2.1.2 Rising awareness and focus about facial aesthetics in developed countries
      • 3.2.1.3 Increasing demand for minimally invasive cosmetic procedures
      • 3.2.1.4 Increasing number of professionals and facilities in developed countries
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost associated with aesthetic injectables
      • 3.2.2.2 Side effects associated with these procedures
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Botulinum toxin
    • 5.2.1 Botulinum toxin A
    • 5.2.2 Botulinum toxin B
  • 5.3 Dermal fillers
    • 5.3.1 By product type
      • 5.3.1.1 Hyaluronic acid
      • 5.3.1.2 Calcium hydroxyapatite
      • 5.3.1.3 Poly-L-lactic acid
      • 5.3.1.4 Polymethyl-methacrylate microspheres (PMMA)
      • 5.3.1.5 Collagen
      • 5.3.1.6 Fat fillers
      • 5.3.1.7 Other dermal fillers
    • 5.3.2 By application
      • 5.3.2.1 Face lift
      • 5.3.2.2 Facial correction
      • 5.3.2.3 Wrinkles reduction
      • 5.3.2.4 Acne scar
      • 5.3.2.5 Lipoatrophy
      • 5.3.2.6 Lip enhancement
      • 5.3.2.7 Hip augmentation
      • 5.3.2.8 Breast enhancement
      • 5.3.2.9 Hand rejuvenation
      • 5.3.2.10 Penis enlargement
      • 5.3.2.11 Blepharoplasty
      • 5.3.2.12 Neck & chin lift
      • 5.3.2.13 Other applications

Chapter 6 Market Estimates and Forecast, By Gender, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Female
  • 6.3 Male

Chapter 7 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 15 - 30
  • 7.3 31 - 40
  • 7.4 41 - 50
  • 7.5 51 - 60
  • 7.6 > 60

Chapter 8 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Dermatology clinics
  • 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 AbbVie Inc (Allergan Plc.)
  • 10.2 Bio-Med Private Limited
  • 10.3 Bioxis Pharmaceuticals
  • 10.4 Cytophil, Inc.
  • 10.5 Galderma S.A.
  • 10.6 Ipsen SA
  • 10.7 Laboratories Vivacy SAS
  • 10.8 Merz Pharma GmbH & Co. KGaA.
  • 10.9 Mesoestetic
  • 10.10 Sinclair Pharma (Huadong Medicine Co., Ltd)
  • 10.11 Suneva Medical, Inc
  • 10.12 Teoxane Laboratories